News | April 23, 2022
Covid-19 vaccine protection against hospitalization wanes
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
The business is a recognized leader in managing Covid-19 and mRNA research programs
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The peptide-based vaccine induces a t cell-dependent response
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The total investment is in the region of Rs 200 crore
Both companies have been selected for stand-by production by German government
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Subscribe To Our Newsletter & Stay Updated
